Structured Abstract
Introduction People with Down syndrome (DS) often develop Alzheimer disease (AD). Here we asked whether ultrasensitive plasma immunoassays for a tau N-terminal fragment (NT1-tau) and Aβ isoforms predict cognitive impairment.
Methods Plasma NT1-tau, Aβ37, Aβ40, and Aβ42 levels were measured in a longitudinal discovery cohort (N = 85 participants, 220 samples) and a cross-sectional validation cohort (N = 239). We developed linear models and predicted values in the validation cohort.
Results Linear mixed models for NT1-tau, Aβ42, and Aβ37:42 were significant for age, there was no main effect of time in the discovery cohort. In cross-sectional models, NT1-tau and Aβ42 increased with age. NT1-tau predicted DLD scores. The discovery cohort linear model for NT1-tau predicted NT1-tau levels in the validation cohort.
Discussion NT1-tau correlates with age and worse cognition in DS. Further validation of NT1-tau and other plasma biomarkers of AD neuropathology in DS cohorts is important for clinical utility.
- Down syndrome
- Alzheimer disease
- tau
- Aβ
- plasma
- biomarker
Competing Interest Statement
DJS is a director and consultant to Prothena Biosciences. The other authors declare no conflicts of interest.
Funding Statement
This work was supported by grants from the National Institutes of Health, R01 AG021912, R01 HD065160, R56 AG061837, P01 HD035897, AG014673, U01 AG051406, U01 AG051412, U19 AG068054, and funds from the New York State Office for People with Developmental Disabilities. The work was also supported by the Davis Alzheimer Prevention Program. The work contained in this publication was also supported through the following National Institutes of Health Programs: The Alzheimer Disease Research Centers Program (P50 AG008702, P30 AG062421, P50 AG16537, P50 AG005133, P50 AG005681, P30 AG066519, P30 AG06648, P30 AG06642, P30 AG072946, P30 AG06644, and P30 AG062715), the Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers Program (U54 HD090256 and U54 HD087011), the National Centers for Advancing Translational Sciences (UL1 TR001873, UL1 TR002373, UL1 TR001414, UL1 TR001857, UL1 TR002345), the National Centralized Repository for Alzheimer Disease and Related Dementias (U24 AG21886), and DS-Connect (The Down Syndrome Registry) supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The authors thank the ABC-DS study participants (adults with Down syndrome and their siblings), their families and care providers, and the ABC-DS research and support staff for their invaluable contributions to this study. The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Kentucky gave ethical approval for this work. Multiple IRBs participating in the ABC-DS study gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
